Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet; 20230101, Issue: Preprints
- Subject
- Language
- ISSN
- 01406736; 1474547X